Does NeuroDerm Ltd. (NASDAQ:NDRM) have hidden weakness?


Shares of NeuroDerm Ltd. (NASDAQ:NDRM) last traded at $28.75. The firm’s performance so far in this year is 29.50%. The 200-day simple moving average is 30.87%. It is considered a key indicator by market analysts and traders for determining the long-term trend. The price mark in a market that coincides with it is recognized as a key support when price moves above the 200-day SMA or resistance when stock price is below this level.

As per recent filings, NeuroDerm Ltd. (NASDAQ:NDRM) has an insider ownership of 52.73%.

Neuroderm Ltd. is a clinical-stage pharmaceutical company. It is developing next-generation treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson’s disease (PD). Its product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. NeuroDerm Ltd. is headquartered in Rehovot, Israel.

NeuroDerm Ltd. (NASDAQ:NDRM) has been storming Wall Street with promising press release. Recently, the firm reported that according to the March 2017 analysis commissioned by RetailMeNot and performed by Forrester Consulting, the firm’s mobile marketing solutions result in a 3-year, risk-adjusted ROI of 4.3x.

The Barchart Technical Opinion rating is a 32% Buy with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Strong. The market is in highly overbought territory. Beware of a trend reversal.

The Exponential Moving Average is a tool same as a simple moving average, with the only difference being a weighting factor used by EMA that exponentially declines from the recent data point. EMA analysis checks the averages for different period, including short term that is 5 days and 13 days, intermediate term for 20 days and long term of 50 days EMA. The bullish signals are received when they trade above trailing EMAs and below the prevailing price and vice versa. EMA signals include crossovers and EMA convergences The long term and short term EMA’s of 25.41 and 24.44 are lower than the current trading price suggesting a bullish pattern in both short term as well as long term. .

The relative strength index can be marked as a momentum oscillator that is able to read the velocity and magnitude of equity price changes. The current RSI is 64.96 suggesting a bullish price action.

NeuroDerm Ltd. (NASDAQ:NDRM) is all set to post its earnings on May 25. As per Zack’s analyst ratings, NeuroDerm Ltd. (NASDAQ:NDRM) presently has an average brokerage rating of . On a scale of 1 – 5, a rating of 2 or 1 would indicate a buy, and a 4 or 5 rating would signify a sell while a rating of 3 indicates a hold.

As such, while we consider NeuroDerm Ltd. (NASDAQ:NDRM) represents a convincing growth story exposed to different attractive markets, it would be enticing to see what it brings for long-term investors.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.